Recently we've rececived several questions from members about how to evaluate the different clinical pathways programs (like Innovent, Via Oncology, and P4) currently on the market. At their core, all pathways programs entail some methodology that helps providers to determine the most effective, least toxic and least costly treatment for any one patient. In addition, they all include some mechanism for monitoring the use of recommended pathways and incentives to encourage physicians to adhere to the pathways. The goal is to increase evidence-based care, reduce unnecessary variation, and control costs. Given the commonalities across vendors, how do you choose between programs?
My colleague Marie Copoulos, who led our research on pathways this year, was kind enough to share her thoughts about some of the key questions that cancer providers should be asking. According to her research, there are significant differences between pathways programs. Here are her suggestions for questions to raise with vendors:
Evaluating Clinical Pathways Programs